PosterSessionOnline

EUROPEAN HEMATOLOGY ASSOCIATION

22nd Congress of EHA

22-25 June 2017 Madrid

N. Poster

Poster title

Applicant name

Status


151-P	TARGETED SINGLE CELL SEQUENCING TO IDENTIFY MUTATIONAL HIERARCHY IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA	Jolien De Bie	Received

152-P	BCL-2 INHIBITION AS NEW THERAPEUTIC OPPORTUNITY FOR RPL10 R98S MUTANT PEDIATRIC T-ALL	Kim Kampen	Received

153-P	TRANSLATOME ANALYSIS OF THE T-ALL ASSOCIATED RIBOSOMAL PROTEIN L10 R98S MUTATION REVEALS ALTERED SERINE METABOLISM	Laura Fancello	Received

155-P	TP53 MUTATIONS DISRUPTING DNA BINDING LEAD TO CHEMOTHERAPY RESISTANCE IN ACUTE LYMPHOBLASTIC LEUKEMIA	Malwine Pogodzinski	Received

156-P	GENETIC ACTIVATION AND THERAPEUTIC TARGETING OF PIM1 IN T-CELL ACUTE LYMPHOBLASTIC LYMPHOMA	Renate De Smedt	Received

157-P	IL-7 FLEXIBLY REGULATES AUTOPHAGY-DEPENDENT VIABILITY OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA CELLS	Daniel Ribeiro	Received

158-P	PRECLINICAL ACTIVITY OF ENTOSPLETINIB IN CHILDHOOD B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA	Sarah Tasian	Received

159-P	PHARMACOLOGICAL ACTIVITY OF CB-103 – AN ORAL PAN-NOTCH INHIBITOR WITH A NOVEL MODE OF ACTION	Raj Lehal	Received

160-P	IKZF1?4-7 CAN BE EASILY SCREENED BY PCR BUT DOES NOT PREDICT OUTCOME IN ADULTS WITH ACUTE LYMPHOBLASTIC LEUKAEMIA; DATA FROM 490 PATIENTS ENROLLED ON THE UKALL14 TRIAL.	Rachel Mitchell	Received

161-P	PROGNOSTIC SIGNIFICANCE OF MINIMAL RESIDUAL DISEASE DETECTED BY MLL FUSION GENE TRANSCRIPTS IN INFANT ACUTE LYMPHOBLASTIC LEUKEMIA. UPDATED RESULTS OF 76 PATIENTS ENROLLED INTO MLL-BABY STUDY	Grigory Tsaur	Received

162-P	PRO-T CELL ALL/LBL: AN ULTRA-HIGH RISK CD2-NEGATIVE DISEASE SUBTYPE IN ADULTS DEFINED BY FLOW CYTOMETRY	Beata Ostrowska	Received

163-P	CLINICAL SIGNIFICANCE OF END OF INDUCTION MINIMAL RESIDUAL DISEASE IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN COMPLETE REMISSION AFTER A SINGLE CHEMOTHERAPY COURSE	Renato Bassan	Received

164-P	RESULTS FROM UKALL60+, A UK/HOVON COLLABORATIVE PHASE 2 STUDY IN ELDERLY PATIENTS WITH UNTREATED ACUTE LYMPHOBLASTIC LEUKAEMIA	Nick Morley	Received

165-P	CLINICAL OUTCOMES OF ELDERLY ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA – A SINGLE INSTITUTION EXPERIENCE	Kevin Miller	Received

166-P	MANAGEMENT AND OUTCOME OF ADULT PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS TREATED AT THE "SAPIENZA" UNIVERSITY BETWEEN 1996 AND 2016	Sabina Chiaretti	Received

167-P	THE TETRASPANIN CD9 IS A PROGNOSTIC MARKER FOR PREDICTING SURVIVAL OUTCOMES OF PEDIATRIC B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA	Kam Tong Leung	Received

168-P	PEDIATRIC MLL ACUTE LEUKEMIA PATIENTS SHOW DIFFERENTIAL HDAC EXPRESSION	Nerea Vega-Garcia	Received

169-P	MINIMAL DISSEMINATED DISEASE DETECTION BY FLOWCYTOMETRIC IMMUNOPHENOTYPING IN T-CELL ACUTE LYMPHOBLASTIC LYMPHOMA	Ganesh Kumar Viswanathan	Received

170-P	INOTUZUMAB OZOGAMICIN IN COMBINATION WITH LOW-INTENSITY CHEMOTHERAPY (MINI-HYPER-CVD) AS FRONTLINE THERAPY FOR OLDER PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA: UPDATED RESULTS FROM A PHASE I/II TRIAL	Nicholas Short	Received

171-P	RECURRENT MYB REARRANGEMENT IN BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM	Kyogo Suzuki	Received

172-P	BRANCHED CHAIN AMINO ACID METABOLISM REGULATES ALPHA-KETOGLUTARATE HOMEOSTASIS RESEMBLING MUTANT-IDH DRIVEN DNA HYPERMETHYLATION IN AML	Simon Raffel	Received

173-P	NUCLEAR RE-LOCALIZATION OF NPM1C+ INDUCES DIFFERENTIATION AND CELL GROWTH ARREST	Lorenzo Brunetti	Received

174-P	THE LONG NON-CODING RNA HOXB-AS3 REGULATES RIBOSOMAL BIOGENESIS IN NPM1-MUTATED ACUTE MYELOID LEUKEMIA	Dimitrios Papaioannou	Received

175-P	A DUAL BH3-MIMETIC APPROACH TARGETING BOTH BCL-2 AND MCL1 IS HIGHLY EFFICACIOUS AND WELL-TOLERATED IN ACUTE MYELOID LEUKEMIA	Donia Moujalled	Received

176-P	THE PMLC62A/C65A KNOCK-IN MOUSE MODEL PROVIDES EVIDENCE FOR THE ROLE OF NUCLEAR BODY DISRUPTION IN THE PATHOGENESIS OF ACUTE PROMYELOCYTIC LEUKEMIA	Edwige Voisset	Received

179-P	ACUTE MYELOID LEUKEMIA EVOLUTION CAN BE RECONSTRUCTED BY ANALYSIS OF NON-LEUKEMIC CELLULAR SUBCOMPARTMENTS AND MULTI-LINEAGE ENGRAFTED MICE	Borhan Saeed	Received

180-P	THE ESSENTIAL ROLE OF THE ENHANCERS OF POLYCOMB EPC1 AND EPC2 IN MLL-AF9 ACUTE MYELOID LEUKAEMIA IS A ´COMPLEX´ STORY	Niamh Mannion	Received

181-P	STROMA-DERIVED FACTORS STIMULATE JAK/STAT SIGNALING IN AML CELLS RESULTING IN RESISTANCE TO BCL2 INHIBITOR VENETOCLAX	Riikka Karjalainen	Received

183-P	H3K27ME3 LEVEL ON THE HIST1 CLUSTER: A POWERFUL EPIGENETIC BIOMARKER THAT STRATIFIES TWO GROUPS OF NPM1-MUTATED AML DIFFERING IN THEIR OUTCOME AND EXPRESSION PROFILE	Sylvain Garciaz	Received

187-P	UNRAVELING EPIGENOMIC REGULATION IN THE EVOLUTION OF RELAPSING PEDIATRIC AML	Caroline Wiggers	Received

188-P	MECHANISTICALLY INFORMED COMBINATIONS OF SY-1425, A POTENT AND SELECTIVE RAR? AGONIST, WITH HYPOMETHYLATING OR ANTI-CD38 TARGETED AGENTS IN AML AND MDS	Michael Mckeown	Received

189-P	FLT3 INHIBITION OVERCOMES RESISTANCE TO THE BCL-2 SELECTIVE ANTAGONIST, VENETOCLAX, IN FLT3-ITD MUTANT AML MODELS	Deepak Sampath	Received

190-P	SPECIFIC TARGETING OF ACUTE MYELOID LEUKEMIA STEM CELLS BY INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 7	Linda Smit	Received

192-P	PROGNOSTIC IMPACT OF SOMATIC MUTATION CLEARANCE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA	Koichi Takahashi	Received

193-P	DO EDUCATION AND INCOME AFFECT TREATMENT AND OUTCOME IN ACUTE MYELOID LEUKEMIA IN A TAX-SUPPORTED HEALTH CARE SYSTEM? A DANISH NATIONAL POPULATION-BASED COHORT STUDY	Lene SG Østgård	Received

194-P	IDENTIFICATION OF PATTERNS IN CO-OCCURRING MUTATIONS IN AML PATIENTS WITH GERMLINE AND SOMATIC RUNX1 MUTATIONS	Uma Borate	Received

196-P	MULTIPLE LEUKEMIC STEM CELL MARKER EXPRESSION IS ASSOCIATED WITH POOR PROGNOSIS IN DE NOVO ACUTE MYELOID LEUKEMIA	Tomohiro Yabushita	Received

197-P	NEXT GENERATION SEQUENCING TARGETED PANEL FOR MINIMAL RESIDUAL DISEASEMONITORING IN ACUTE MYELOID LEUKEMIA	Valerie Mcclain	Received

198-P	IS IT POSSIBLE TO RELIABLY DETECT CLINICALLY-RELEVANT BIALLELIC CEBPA GENE MUTATIONS USING NGS PANELS?	Marta Fernandez-Mercado	Received

200-P	NUMBER OF TP53 ABNORMALITIES AND THEIR CLINICAL RELEVANCE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES	Guillermo Montalban-Bravo	Received

201-P	VADASTUXIMAB TALIRINE PLUS HYPOMETHYLATING AGENTS (HMA): A WELL-TOLERATED REGIMEN WITH HIGH REMISSION RATE IN FRONTLINE OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML)	Farhad Ravandi	Received

202-P	ACUTE MYELOID LEUKEMIA WITH INTERMEDIATE-RISK CYTOGENETICS AND A FAVORABLE GENOTYPE: PROGNOSTIC FACTORS AND RESULTS IN PATIENTS TREATED ACCORDING THE SPANISH CETLAM PROTOCOLS.	J. Sierra	Received

204-P	A PHASE 2 STUDY OF GLASDEGIB (PF-04449913) IN COMBINATION WITH CYTARABINE AND DAUNORUBICIN IN UNTREATED PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) OR HIGH-RISK MYELODYSPLASTIC SYNDROME (MDS)	Jorge Cortes	Received

205-P	CM942 IS A NEW SMALL MOLECULE THAT TARGETS SET-PP2A INTERACTION AND INHIBITS GROWTH OF ACUTE MYELOID LEUKEMIA CELLS	Patricia García-Ramírez	Received

206-P	CLONAL HETEROGENEITY IN LEUKEMIC STEM CELLS FROM PATIENTS WITH ACUTE MYELOID LEUKEMIA	Linda Manta	Received

207-P	TREATMENT OF PRACINOSTAT AND AZACITIDINE IN ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML): CORRELATION BETWEEN MUTATION CLEARANCE AND CLINICAL RESPONSE	Koichi Takahashi	Received

209-P	A RANDOMIZED PHASE II STUDY OF IDARUBICIN AND CYTARABINE WITH EITHER CLOFARABINE (CIA) OR FLUDARABINE (FIA) IN ADULTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA	Nicholas Short	Received

210-P	OVERALL SURVIVAL AND TRANSPLANTATION IN PATIENTS WITH FLT3 MUTATIONS: SUBGROUP ANALYSIS OF A PHASE 3 STUDY OF CPX-351 VERSUS 7+3 IN OLDER ADULTS WITH NEWLY DIAGNOSED, HIGH-RISK ACUTE MYELOID LEUKEMIA	Bruno Medeiros	Received

211-P	NIVOLUMAB MAINTENANCE THERAPY FOR PATIENTS WITH HIGH-RISK ACUTE MYELOID LEUKEMIA (AML) IN REMISSION	Tapan Kadia	Received

212-P	HIGHER EXPRESSION OF LONG NON-CODING RNA KIAA0125 IS ASSOCIATED WITH CHARACTERISTIC CLINICAL AND BIOLOGICAL FEATURES AND IS AN INDEPENDENT POOR PROGNOSTIC FACTOR IN ACUTE MYELOID LEUKEMIA	Sheng-Yu Hung	Received

213-P	LEUKEMIC STEM CELLS CAN BE DETECTED IN A CONSIDERABLE PERCENTAGE OF PATIENTS WITH ACUTE MYELOID LEUKEMIA AT DIAGNOSIS AND IS A SIGNIFICANT PROGNOSTIC FACTOR	Olga Pérez-López	Received

214-P	POST-REMISSIONAL AND PRE-TRANSPLANT ROLE OF MINIMAL RESIDUAL DISEASE DETECTED BY WT1 IN ACUTE MYELOID LEUKEMIA: A RETROSPECTIVE COHORT STUDY	Chiara Frairia	Received

217-P	OUTCOME OF PATIENTS WITH INTRAVASCULAR B-CELL LYMPHOMA, A RETROSPECTIVE STUDY CONDUCTED ON BEHALF OF THE LYMPHOMA STUDY ASSOCIATION (LYSA) GROUP	Antoine Bonnet	Received

218-P	OUTCOME OF ELDERLY DLBCL PATIENTS (= 80 YEARS) TREATED WITH ANTHRACYCLINE BASED CHEMOTHERAPY; R-CHOP DOSE REDUCTION IS NOT NECESSARY FOR EVERYBODY	Marek Trnený	Received

219-P	IMPROVED SURVIVAL IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL) UP TO AGE 70 ONLY: A POPULATION-BASED STUDY ON INCIDENCE, PRIMARY TREATMENT AND SURVIVAL IN THE NETHERLANDS, 1989-2015	Avinash Dinmohamed	Received

220-P	CLINICAL CHARACTERISTICS AND LONG-TERM RESULTS OF TREATMENT OF DIFFUSE LARGE HEPATITIS C - ASSOCIATED NON-HODGKIN LYMPHOMA (DLBCL + C).	Sergey Lepkov	Received

223-P	RELAPSE CHARACTERISTICS AND THE ROLE OF SURVEILLANCE COMPUTED TOMOGRAPHY IN AGGRESSIVE NON-HODGKIN LYMPHOMA	Ka-Won Kang	Received

224-P	A MULTI-CENTER STUDY OF GLIDE CHEMOTHERAPY CONSOLIDATED WITH AUTOLOGOUS STEM CELL TRANSPLANTATION FOR NEWLY DIAGNOSED STAGE IV AND RELAPSED EXTRANODAL NATURAL KILLER/T-CELL LYMPHOMA PATIENTS	Jie Ji	Received

225-P	LONG TERM FOLLOW-UP OF PATIENTS WITH PERIPHERAL T-CELL LYMPHOMAS TREATED WITH IFOSFAMIDE, ETOPOSIDE, EPIRUBICIN / INTERMEDIATE METHOTREXATE AND AUTOLOGOUS STEM CELL TRANSPLANTATION	Michal Sieniawski	Received

226-P	IDENTIFICATION OF A NOVEL GERMLINE MECOM / EVI1 VARIANT THAT RUNS IN A PEDIGREE WITH RADIOULNAR SYNOSTOSIS AND AMEGAKARYOCYTIC THROMBOCYTOPENIA AND PREDISPOSES TO ADULT ONSET MYELOID MALIGNANCY	Tim Ripperger	Received

227-P	LOSS OF THE HOMOLOGOUS RECOMBINATION GENE RAD51 LEADS TO FANCONI ANEMIA-LIKE SYMPTOMS IN ZEBRAFISH	Jan Botthof	Received

228-P	A NOVEL TELOMERASE RNA COMPONENT (TERC) VARIANT IN A FAMILY WITH MACROCYTOSIS AND MILD VARIABLE CYTOPENIAS	Claire Burney	Received

229-P	GENERATION OF X-LINKED DYSKERATOSIS CONGENITA-LIKE HUMAN HEMATOPOIETIC STEM CELLS	Guillermo Guenechea	Received

230-P	STUDY OF EXTRACELLULAR VESICLES ROLES IN THE PATHOPHYSIOLOGY OF THROMBOSIS IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS DURING ECULIZUMAB TREATMENT: A PILOT PROSPECTIVE LONGITUDINAL CLINICAL STUDY	Adeline Wannez	Received

231-P	TELOMERE LENGTH SCREENING TRIGGERED BY CLINICAL SUSPICION FOR CLASSICAL AND/OR CRYPTIC DYSKERATOSIS CONGENITA –PROSPECTIVE RESULTS FROM THE AACHEN TELOMEROPATHY REGISTRY	Fabian Beier	Received

233-P	CLINICAL AND GENETIC DIVERSITY IN DIAMOND-BLACKFAN ANAEMIA: AN UPDATE FROM THE UNITED KINGDOM	Deena Iskander	Received

234-P	BONE MARROW FAILURE SECONDARY TO NOVEL/KNOWN PRIMARY IMMUNODEFICIENCY-RELATED MUTATIONS. A SINGLE CENTER ANALYSIS	Maurizio Miano	Received

236-P	GERMLINE RARE VARIANT ASSOCIATION ANALYSIS IN CHRONIC LYMPHOCYTIC LEUKEMIA	Jennifer Brown	Received

237-P	DIFFERENTIAL ENHANCER TRANSCRIPTION ASSOCIATED WITH RISK ALLELE GENOTYPE IN CLL	Jennifer Brown	Received

238-P	BIALLELIC TP53 GENE MUTATIONS DUE TO COPY-NEUTRAL LOSS OF HETEROZYGOSITY AND MONOALLELIC MUTATIONS IN ABSENCE OF 17P DELETION OCCUR IN CLL WITH COMPARABLE FREQUENCY	Karla Plevova	Received

239-P	INTERGRATED OLIGO/SNP ARRAY- AND NEXT GENERATION SEQUENCING BASED ANALYSIS IS REQUIRED TO DETERMINE TP53/17P STATUS IN CLL PATIENTS	Marian Stevens-Kroef	Received

240-P	CYTOGENETIC CLONAL EVOLUTION OCCURS AT THE TIME OF DISEASE PROGRESSION DURING IBRUTINIB THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY CLL.	Philip Thompson	Received

241-P	LANDSCAPE OF SOMATIC MUTATIONS AND THEIR IMPACT ON RESPONSE AND OUTCOMES FROM LENALIDOMIDE-BASED THERAPIES IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)	Boyu Hu	Received

242-P	HIGH THROUGHPUT IMMUNOPROFILING OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS ASSIGNED TO STEREOTYPED SUBSET #4: NOVEL INSIGHTS INTO THE DEPTH, DIVERSITY AND TEMPORAL DYNAMICS OF CLONAL EVOLUTION	Lesley Sutton	Received

243-P	FAILED HYDROXYMETHYLATION CONTRIBUTES TO A CHRONIC LYMPHOCYTIC LEUKEMIA SPECIFIC EPIGENOTYPE	Katarzyna Szarc Vel Szic	Received

244-P	DNA METHYLATION PROFILING IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS CARRYING STEREOTYPED B-CELL RECEPTORS: A DIFFERENT CELLULAR ORIGIN FOR SUBSET #2?	Sujata Bhoi	Received

245-P	ADDING OBINUTUZUMAB TO IBRUTINIB ENHANCES DEPLETION OF CLL CELLS IN PERIPHERAL BLOOD AND BONE MARROW AFTER 1 & 6 MONTHS COMBINED THERAPY INITIAL RESULTS FROM THE BLOODWISE TAP ICICLLE EXTENSION STUDY	Andrew Rawstron	Received

246-P	CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS EXPRESSING THE LIGHT CHAIN IGLV3-21 HAVE A POOR PROGNOSIS INDEPENDENTLY OF HEAVY CHAIN IGHV3-21 OR THE IGHV MUTATIONAL STATUS	Basile Stamatopoulos	Received

249-P	RESULTS OF A PHASE II MULTICENTER STUDY OF OBINUTUZUMAB PLUS BENDAMUSTINE IN PTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)	Alexey Danilov	Received

250-P	RELATIVE SURVIVAL REACHES A PLATEAU IN HAIRY CELL LEUKEMIA (HCL): A POPULATION-BASED STUDY ON INCIDENCE, PRIMARY TREATMENT AND SURVIVAL AMONG 1,427 PATIENTS DIAGNOSED IN THE NETHERLANDS, 1989-2014	Avinash Dinmohamed	Received

251-P	CUMULATIVE ILLNESS RATING SCALE (CIRS) PROVIDES PROGNOSTIC INFORMATION BEYOND THE INTERNATIONAL PROGNOSTIC INDEX FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL-IPI): AN ACROSS-TRIAL ANALYSIS BY THE GCLLSG	Valentin Goede	Received

252-P	A PHASE II RANDOMISED STUDY INVESTIGATING THE EFFICACY OF STANDARD OR HIGH-DOSE OFATUMUMAB IN COMBINATION WITH CHEMOTHERAPY IN RELAPSED CHRONIC LYMPHOCYTIC LEUKAEMIA	David Allsup	Received

253-P	FINAL RESULTS OF THE PHASE IB GALTON TRIAL IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): DURABLE REMISSIONS WITH FRONTLINE OBINUTUZUMAB (G) PLUS FLUDARABINE/CYCLOPHOSPHAMIDE (G-FC) OR BENDAMUSTINE (G-B)	Jennifer Brown	Received

254-P	THE PROGNOSTIC SIGNIFICANCE OF CLL-IPI AFTER REDUCED INTENSITY CONDITIONING ALLOGENEIC STEM CELL TRANSPLANT IN CHRONIC LYMPHOCYTIC LEUKEMIA: THE MAYO CLINIC EXPERIENCE	Theodora Anagnostou	Received

255-P	IMPACT OF ABCG2, OCT1 AND ABCB1 (MDR1) ON TREATMENT FREE REMISSION IN AN EUROSKI SUBTRIAL	Sébastien Rinaldetti	Received

256-P	HLA-G MOLECULES AND CLINICAL OUTCOME IN CHRONIC MYELOID LEUKEMIA	Giovanni Caocci	Received

257-P	DURABLE TREATMENT-FREE REMISSION (TFR) AFTER STOPPING SECOND-LINE NILOTINIB (NIL) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): ENESTOP 96-WK UPDATE	Timothy Hughes	Received

258-P	NILOTINIB-INDUCED METABOLIC DYSFUNCTION: INSIGHTS FROM A TRANSLATIONAL PILOT STUDY USING IN VITRO ADIPOCYTE MODELS AND PATIENT COHORTS	Sudeep Pushpakom	Received

259-P	EARLY PREDICTION OF THE MOLECULAR RESPONSE TO BCR-ABL1 TYROSINE KINASE INHIBITORS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA	Su Young Jung	Received

261-P	A HIGH SENSITIVITY HIGH SPECIFICITY DIGITAL PCR ASSAY FOR BCR-ABL	Georg-Nikolaus Franke	Received

262-P	VALIDATION OF THE EUTOS LONG TERM SURVIVAL (ELTS) SCORE IN DUTCH CML-PATIENTS	Inge Geelen	Received

263-P	FINAL STUDY RESULTS OF DISCONTINUATION OF DASATINIB IN PATIENTS WITH CML WHO MAINTAINED DEEP MOLECULAR RESPONSE FOR LONGER THAN ONE YEAR (DADI TRIAL) AFTER THREE YEARS OF FOLLOW-UP	Hirohisa Nakamae	Received

264-P	ACUTE MYELOID LEUKEMIA ALTERS THE PERMEABILITY OF THE BONE MARROW VASCULAR MICROENVIRONMENT, FOSTERING DISEASE PROGRESSION AND DRUG RESISTANCE	Diana Passaro	Received

265-P	BUILDING HUMAN BONE MARROW-LIKE MODELS TO STUDY NICHE INTERACTIONS	Richard Groen	Received

267-P	TEMPLATED V(D)J INSERTIONS ARE A NOVEL BIOLOGIC MECHANISM FOR B-CELL RECEPTOR REPERTOIRE DIVERSIFICATION	Marvyn Koning	Received

268-P	TARGETING THE CASPASE / NOX2 AXIS TO MODULATE MACROPHAGE POLARIZATION	Stéphanie Solier	Received

269-P	MULTIPLE MYELOMA-POLARIZED M2C MACROPHAGES PROMOTE A TUMOR-SUPPORTIVE OSTEOLYTIC MICROENVIRONMENT VIA CXCL13	Katia Beider	Received

270-P	RE-ORDERING THE B CELL DEVELOPMENT HIERARCHY IN HUMAN FETAL BONE MARROW: CHARACTERISATION OF A NOVEL HUMAN FETAL B PROGENITOR	Sorcha O´Byrne	Received

271-P	HUNDREDS OF EMBRYONIC HEMATOPOIETIC PRECURSORS CONTRIBUTE TO LIFE-LONG HEMATOPOIESIS	Miguel Ganuza Fernandez	Received

272-P	A20 RESTRAINS THYMIC REGULATORY T CELL DEVELOPMENT	Tobias Haas	Received

273-P	THE TRANSCRIPTION FACTOR C/EBPG REGULATES MAST CELL DEVELOPMENT AND FUNCTION	Miroslava Kardosova	Received

274-P	TRANSCRIPTIONAL DIVERSITY AND DEVELOPMENTAL POTENTIAL OF EARLY HEMATOPOIETIC PROGENITORS REVEALED BY CELLULAR BARCODING AND TRANSCRIPTOME-WIDE PROFILING	Diana Tronik-Le Roux	Received

275-P	LONG-TERM OUTCOME OF PATIENTS WITH NODULAR LYMPHOCYTE-PREDOMINANT HODGKIN LYMPHOMA (NLPHL) TREATED WITHIN THE RANDOMIZED HD7-HD15 TRIALS: AN ANALYSIS FROM THE GERMAN HODGKIN STUDY GROUP (GHSG)	Dennis Eichenauer	Received

276-P	ADVANCED HODGKIN LYMPHOMA IN THE EAST OF ENGLAND CANCER NETWORK: A 10-YEAR COMPARATIVE ANALYSIS OF OUTCOMES FOR ABVD AND ESCALATED-BEACOPP TREATED PATIENTS AGED 16–59	James Russell	Received

277-P	IMPACT ON SURVIVAL OF EARLY DETECTION OF RECURRENCE IN THE FOLLOW-UP OF HIGH RISK HODGKIN LYMPHOMA IN FIRST COMPLETE REMISSION	Novella Pugliese	Received

278-P	LATER LINE DRUG TREATMENT PATTERNS OF CLASSICAL HODGKIN´S LYMPHOMA (CHL) PATIENTS IN CANADA, FRANCE, GERMANY AND THE UNITED KINGDOM	Katherine Byrne	Received

279-P	CHEMOTHERAPY AND RADIATION IMPROVE SURVIVAL IN EARLY STAGE CLASSICAL HODGKIN LYMPHOMA, A STATEWIDE CANCER REGISTRY ANALYSIS.	Hayder Saeed	Received

280-P	THE IMPACT OF TREATMENT WITH BRENTUXIMAB VEDOTIN ON OVERALL SURVIVAL OF PATIENTS WITH HODGKIN LYMPHOMA RELAPSED AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION. A NATIONWIDE POPULATION BASED ANALYSIS	Panagiotis Tsirigotis	Received

281-P	NIVOLUMAB FOR RELAPSED OR REFRACTORY HODGKIN LYMPHOMA: EXPERIENCE IN TURKEY	Burhan Ferhanoglu	Received

283-P	FDG PET-CT MAYBE A USEFUL TOOL TO IDENTIFY DOXORUBICIN INDUCED CARDIOTOXICITY IN HODGKIN LYMPHOMA	Gianmario Sambuceti	Received

284-P	ELEVATED SYSTEMIC HEME AND IRON LEVELS AS RISK FACTORS FOR VASCULAR DYSFUNCTION AND ATHEROSCLEROSIS: EVIDENCE FROM B-THALASSEMIA AND HEMOCHROMATOSIS COHORT STUDIES	Francesca Vinchi	Received

287-P	ASSESSMENT OF THE PERFORMANCE OF A WIDELY AVAILABLE T2/R2 LIVER IRON CONCENTRATION METHOD USED IN CLINICAL PRACTICE IN A POPULATION OF THALASSEMIA PATIENTS	Tim St Pierre	Received

289-P	WHEN IRON LEADS TO RED CELLS (AND VICE VERSA): A COMPREHENSIVE PHENOTYPE -TOWARDS NGS/WES PATHWAY FOR THE DIAGNOSIS OF RED CELL AND IRON DISORDERS	Patricia Aguilar Martinez	Received

290-P	CHANGES IN LIVER IRON CONCENTRATION R2 MRI MEASUREMENT ACROSS DIFFERENT CHELATION REGIMENS IN PATIENTS WITH HEMATOLOGICAL DISORDERS: REAL-LIFE EXPERIENCE FROM LICNET	Aurelio Maggio	Received

291-P	IN UTERO IRON STATUS AND AUDITORY NEURAL MATURATION IN FULL TERM INFANTS BORN TO MOTHERS WITH IRON DEFICIENCY ANEMIA	Rania El-Farrash	Received

292-P	THE RELATIONSHIP BETWEEN SERUM FERRITIN AND LIVER IRON CONCENTRATION IN PEDIATRIC CANCER SURVIVORS	Tim St Pierre	Received

293-P	DECREASED MCP-1 LEVELS IN PATIENTS WITH HEREDITARY HEMORRHAGIC TELANGIECTASIA: A CYTOKINE SIGNATURE OF IRON DEFICIENCY	Graça Porto	Received

295-P	GENOME-WIDE ASSOCIATION STUDY OF HODGKIN LYMPHOMA IDENTIFIES HISTOLOGY-SPECIFIC ASSOCIATIONS AND TRANSCRIPTIONAL REGULATORS OF DISEASE SUSCEPTIBILITY	Amit Sud	Received

296-P	SOX11 PROMOTES TUMOR PROTECTIVE MICROENVIRONMENT INTERACTIONS IN MANTLE CELL LYMPHOMA	Patricia Balsas	Received

297-P	AICDA DRIVES EPIGENETIC HETEROGENEITY IN GERMINAL CENTER-DERIVED LYMPHOMAS AND ACCELERATES LYMPHOMAGENESIS	Pilar Dominguez	Received

298-P	XPO1 INHIBITION SYNERGIZES WITH BCR INHIBITION, BLOCKS TUMOR GROWTH AND PROLONGS SURVIVAL IN A BIOLUMINESCENT ANIMAL MODEL OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA	Marta Crespo	Received

300-P	A COMPREHENSIVE PORTRAIT OF THE DNA METHYLOME OF 866 SAMPLES FROM DIFFERENT B CELL NEOPLASMS: BIOLOGICAL INSIGHTS AND CLINICAL APPLICATIONS	Martí Duran-Ferrer	Received

302-P	STAT3 IS CONSTITUTIVELY ACTIVATED AND CAN BE A THERAPEUTIC TARGET OF JAK INHIBITORS IN CHRONIC ACTIVE EPSTEIN-BARR VIRUS INFECTION	Erika Onozawa	Received

303-P	RECURRENT MUTATIONS IN MICRO-RNA BINDING SITES MAY BE POTENTIALLY RELEVANT IN FOLLICULAR LYMPHOMA	Erika Larrea	Received

304-P	CLINICAL IMPACT OF TP53 AND KMT2D MUTATIONS IN MCL RECEIVING HIGH-DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION: UPDATED RESULTS FROM THE FONDAZIONE ITALIANA LINFOMI (FIL) MCL0208 PHASE III TRIAL	Simone Ferrero	Received

305-P	A LOOKBACK AT VWD TYPE 2A AND 2M CLASSIFICATION IN A LARGE COMPREHENSIVE HAEMOPHILIA CENTRE.	Sarah Jaafar	Received

306-P	RETROSPECTIVE EVALUATION OF PHENOTYPE AND MANAGEMENT OF DYSFIBRINOGENEMIA AND HYPODYSFIBRINOGENEMIA IN A COHORT OF ITALIAN PATIENTS.	Cristina Santoro	Received

308-P	PREVALENCE OF GENETIC MARKERS OF OXIDATIVE STRESS IN PATIENTS WITH SEVERE HEMOPHILIA FROM NORTH-WESTERN RUSSIA	Sergey Kapustin	Received

309-P	THE ROLE OF DNA METHYLATION AND EXPRESSION OF MMP-2 AND MMP-9 IN PATHOGENESIS OF INTRACEREBRAL HEMORRHAGE IN CONGENITAL FACTOR XIII DEFICIENCY	Ali Noroozi-Aghideh	Received

311-P	HPA-3A/3A GENOTYPE IS A POSSIBLE RISK FACTOR OF SEVERE HEMORRHAGIC SYNDROME IN PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA	Zotova Irina	Received

312-P	AN ALGORITHM TO IDENTITY CASES OF SEVERE HEMORRHAGE IN ROUTINELY COLLECTED HEALTHCARE DATA	Aukje Kreuger	Received

313-P	MOLECULAR MECHANISMS AND CLINICAL SIGNIFICANCE OF REDUCED PTPN1 EXPRESSION IN MYELODYSPLASTIC SYNDROMES	Masayuki Shiseki	Received

315-P	UPDATED RESULTS FROM PHASE 2 STUDY OF GUADECITABINE FOR PATIENTS WITH UNTREATED INT-2/HIGH RISK MYELODYSPLASTIC SYNDROMES OR CHRONIC MYELOMONOCYTIC LEUKEMIA	Guillermo Montalban-Bravo	Received

316-P	AZACITIDINE IMPROVES OUTCOME IN HIGH RISK MDS PATIENTS WITH CHROMOSOME 7 ABNORMALITIES: RETROSPECTIVE COMPARISON OF GESMD AND GFM REGISTRIES.	María Díez Campelo	Received

317-P	UN UPDATE OF A PHASE II EXPLORATORY STUDY OF OPN-305, A TOLL-LIKE RECEPTOR 2 (TLR-2) ANTIBODY, IN PATIENTS WITH LOWER RISK MYELODYSPLASTIC SYNDROMES WITH PRIOR HYPOMETHYLATING AGENT (HMA) THERAPY	Guillermo Garcia-Manero	Received

318-P	IN PATIENTS UNDEGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR MDS DEVELOPMENT OF CHRONIC GVHD COULD AMELIORATE THE ADVERSE IMPACT OF SPECIFIC SOMATIC MUTATIONS	Juan-Carlos Caballero Berrocal	Received

319-P	VOSAROXIN PLUS AZACITIDINE TREATMENT FOR PATIENTS WITH MYELODYSPLASTIC SYNDROME (MDS): A PHASE 1/COHORT EXPANSION STUDY	Meagan Jacoby	Received

320-P	ADVANCED STAGE MYELOMA IS CHARACTERIZED BY A SIGNIFICANT INCREASE OF MUTATIONS IN GENES ASSOCIATED WITH DRUG RESPONSE	Santiago Barrio	Received

321-P	ILF2-YB1 INTERACTION MODULATES RNA SPLICING TO INDUCE RESISTANCE TO DNA-DAMAGING AGENTS IN 1Q21-AMPLIFIED MULTIPLE MYELOMA	Matteo Marchesini	Received

322-P	PROGNOSTIC IMPLICATION OF SOMATIC MUTATIONS BY NEXT GENERATION SEQUENCING: AN ANALYSIS FROM THE MMRF COMMPASS STUDY IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS.	Mattia D´agostino	Received

323-P	TARGETING GENE DEPENDENCY OF 1Q AMPLIFICATION IN MULTIPLE MYELOMA	Salomon Manier	Received

324-P	DUAL INHIBITION OF DNMT1 AND EZH2 CAN EFFECTIVELY OVERCOME BOTH INTRINSIC AND ACQUIRED RESISTANCE OF MYELOMA CELLS TO IMIDS	Konstantinos Dimopoulos	Received

325-P	MULTILAYER EPIGENOMIC ANALYSES REVEAL OF NEW CANDIDATE ONCOGENES INVOLVED IN THE PATHOGENESIS OF MULTIPLE MYELOMA	Raquel Ordoñez	Received

327-P	PATHOPHYSIOLOGICAL FUNCTIONS AND CLINICAL IMPACT OF THE NEW IMMUNORECEPTOR SLAMF3 IN MULTIPLE MYELOMA	Mariko Ishibashi	Received

328-P	TARGETING CD74 IN MULTIPLE MYELOMA WITH A NOVEL ANTIBODY DRUG CONJUGATE (ADC), STRO-001	Arturo Molina	Received

329-P	GENOTYPE CHARACTERIZATION OF LIGHT CHAIN AMYLOIDOSIS BY WHOLE EXOME SEQUENCING	Isabel Cuenca	Received

330-P	IMPROVED SURVIVAL IN 21,465 MULTIPLE MYELOMA PATIENTS: RESULTS FROM A POPULATION-BASED STUDY	Sigrun Thorsteinsdottir	Received

331-P	PROGNOSTIC IMPLICATIONS OF MULTIPLE CYTOGENETIC HIGH-RISK ABNORMALITIES IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA	Moritz Binder	Received

332-P	LENALIDOMIDE MAINTENANCE VS PLACEBO AFTER STEM CELL TRANSPLANT FOR PATIENTS WITH MULTIPLE MYELOMA: OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL AFTER ADJUSTING FOR TREATMENT CROSSOVER IN CALGB	Philip McCarthy	Received

334-P	EFFICACY AND SAFETY OF DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (DRD) VERSUS RD ALONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED ANALYSIS OF POLLUX	Meletios Dimopoulos	Received

335-P	DARATUMUMAB-BASED COMBINATION REGIMENS IN ELDERLY (=75 YEARS) PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): SUBGROUP ANALYSIS OF THE PHASE 3 CASTOR AND POLLUX STUDIES	Maria-Victoria Mateos	Received

337-P	EVALUATION OF GROWTH DIFFERENTIATION FACTOR-1 (GDF15) AS A NEW BIOMARKER FOR RENAL OUTCOMES IN DIFFERENT COHORTS OF PATIENTS WITH LIGHT CHAIN (AL) AMYLOIDOSIS	Efstathios Kastritis	Received

338-P	AN OPEN-LABEL, PHASE 2 STUDY TO EVALUATE THE ORAL COMBINATION OF IXAZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (ICD) IN TRANSPLANT-INELIGIBLE PATIENTS (PTS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)	Meletios Dimopoulos	Received

339-P	THE ORAL PROTEASOME INHIBITOR IXAZOMIB IN COMBINATION WITH MELPHALAN-PREDNISONE (MP) FOR PATIENTS (PTS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): PHASE 1/2 DOSE-ESCALATION STUDY (NCT01335685)	Jesus San Miguel	Received

340-P	FEASIBILITY AND EFFICACY OF DOSE ADJUSTED MELPHALAN – PREDNISONE – BORTEZOMIB (MPV) IN PATIENTS = 75 YEARS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA; PRELIMINARY RESULTS OF THE PHASE II HOVON 123 STUDY	Sonja Zweegman	Received

342-P	CHEMOTHERAPY BEFORE AND AFTER HEART TRANSPLANTATION FOR PATIENTS WITH ADVANCED CARDIAC AL AMYLOIDOSIS, SINGLE CENTER RESULTS WITH LONG-TERM FOLLOW-UP	Ute Hegenbart	Received

343-P	MM-013 PHASE 2 MULTICENTER STUDY OF POMALIDOMIDE (POM) PLUS LOW-DOSE DEXAMETHASONE (LODEX) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) AND RENAL IMPAIRMENT (RI)	Pieter Sonneveld	Received

345-P	ASSESSMENT OF MOBILIZATION COST FOR MULTIPLE MYELOMA USING 2 DIFFERENT STRATEGIES: HIGH-DOSE CYCLOPHOSPHAMIDE VERSUS PLERIXAFOR. ON BEHALF OF IFM.	Zoe Van De Wyngaert	Received

346-P	SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS OF INDUCTION TREATMENT FOR NEWLY DIAGNOSED TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS	Jin-Chul Kim	Received

347-P	A STUDY OF UTILITY OR FUTILITY OF PERFORMING SKELETAL SURVEYS IN PARAPROTEINAEMIA: A MULTICENTER EXPERIENCE FROM UK	ovini gamage	Received

348-P	SERUM FLC MEASUREMENTS COMPLEMENT BONE MARROW ASSESSMENT TO DETERMINE PROGNOSIS IN MYELOMA PATIENTS ACHIEVING DEEP RESPONSES	Thomas Dejoie	Received

351-P	CYTOGENETIC ABNORMALITIES IN POST-POLYCYTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: CORRELATIONS WITH GENOTYPE AND PHENOTYPE IN THE MYSEC STUDY	Barbara Mora	Received

352-P	MUTATIONAL LANDSCAPE OF MYELODYSPLASTIC SYNDROME/MYELOPROLIFERATIVE NEOPLASM - UNCLASSIFIABLE (MDS/MPN-U)	Prithviraj Bose	Received

353-P	GENOME WIDE DNA METHYLATION PROFILING IS PREDICTIVE OF OUTCOME IN JUVENILE MYELOMONOCYTIC LEUKEMIA	Elliot Stieglitz	Received

354-P	LEUKEMIC TRANSFORMATION OF MYELOPROLIFERATIVE NEOPLASMS: IS NGS PROFILE THE BEST PROGNOSTIC BIOMARKER?	Venton Geoffroy	Received

355-P	INCIDENCE AND OUTCOME OF SECONDARY NON HEMATOLOGICAL CANCERS IN ADULT PATIENTS WITH MASTOCYTOSIS	Massimiliano Bonifacio	Received

356-P	HIGH WBC COUNT WAS THE RISK FACTOR FOR SURVIVAL IN PATIENTS WITH CSF3R- MUTATED CHRONIC NEUTROPHILIC LEUKEMIA	Qian Jiang	Received

357-P	CLINICAL PHENOTYPE AND OUTCOME OF ESSENTIAL THROMBOCYTHEMIA AND PREFIBROTIC MYELOFIBROSIS DIAGNOSED ACCORDING TO THE REVISED 2016 WHO DIAGNOSTIC CRITERIA	Elisa Rumi	Received

358-P	VALIDATION OF THE REVISED IPSET-THROMBOSIS SCORE IN 734 PATIENTS WITH WHO 2016-DEFINED ESSENTIAL THROMBOCYTHEMIA. REPORT OF THE REGISTRO ITALIANO TROMBOCITEMIE (RIT)	Luigi Gugliotta	Received

359-P	CORRELATIONS BETWEEN INFLAMMATORY BIOMARKERS AND INDIVIDUAL SYMPTOMS EXPRESSED BY MYELOFIBROSIS PATIENTS IN THE COMFORT-I TRIAL: ANALYSIS OF BASELINE ASSOCIATIONS AND CHANGES OVER TIME	Holly Geyer	Received

360-P	NOVEL HETEROZYGOUS ITGB3 P.T746DEL MUTATION INDUCING SPONTANEOUS ACTIVATION OF INTEGRIN ?IIB?3 CAUSES AUTOSOMAL DOMINANT MACROTHROMBOCYTOPENIA WITH ABNORMAL ?IIB?3 LOCALIZATION	Naohiro Miyashita	Received

361-P	CHANGES IN THE GENE EXPRESSION PROFILE OF IMMUNE THROMBOCYTOPENIA PATIENTS TREATED WITH ELTROMBOPAG	JM Bastida	Received

362-P	DEFECTIVE PTEN REGULATION CONTRIBUTES TO B CELL HYPERRESPONSIVENESS IN CHRONIC IMMUNE THROMBOCYTOPENIA	shixuan Wang	Received

365-P	NOVEL RUNX1 MUTATIONS IN FAMILIES WITH INHERITED THROMBOCYTOPENIA	Patrizia Noris	Received

367-P	A SINGLE-ARM, OPEN-LABEL, LONG-TERM EFFICACY AND SAFETY STUDY OF SUBCUTANEOUS (SC) ROMIPLOSTIM IN CHILDREN WITH IMMUNE THROMBOCYTOPENIA (ITP)	John Grainger	Received

368-P	NOVEL THIENOPYRIDINES AS POTENT PLATELET INHIBITORS: FUTURE TREATMENTS FOR PLATELET HYPERACTIVITY DISORDERS?	Naif Binsaleh	Received

369-P	PATIENT-REPORTED OUTCOMES AND HEALTHCARE RESOURCE UTILIZATION BEFORE AND DURING TREATMENT WITH ECULIZUMAB: RESULTS FROM THE INTERNATIONAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA REGISTRY	Petra Muus	Received

370-P	ECONOMIC IMPACT OF INTRODUCING AGE-ADJUSTED D-DIMER CUT-OFF LEVELS IN THE DIAGNOSIS STRATEGY OF VENOUS THROMBOEMBOLISM	Pierre Toulon	Received

371-P	IMPACT OF CELLULAR THERAPY ON THE ECONOMIC BURDEN AND SURVIVAL FOLLOWING RELAPSE AFTER HLA IDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ACUTE LEUKEMIA AND MYELODYSPLASTIC SYNDROME.	Silvy Lachance	Received

372-P	ACUTE MYELOID LEUKEMIA (AML) TREATMENT PRACTICE PATTERNS, HEALTHCARE RESOURCE UTILIZATION (HRU) AND COSTS IN A US COMMERCIALLY-INSURED POPULATION	May Hagiwara	Received

374-P	ACCESS TO COMMUNITY CHEMOTHERAPY IMPROVES PATIENT QUALITY OF LIFE	Rachel Iredale	Received

377-P	NUTRITIONAL NEEDS AND PREFERENCES OF MYELOPROLIFERATIVE NEOPLASM PATIENTS: PHASE IA OF THE NUTRIENT STUDY	Robyn Scherber	Received

378-P	DO PHYSICIANS NEED HELP TO ADEQUATELY INFORM AND SUPPORT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA? RESULTS FROM A QUALITATIVE STUDY IN GREECE	Christina Karamanidou	Received

379-P	OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PATIENTS WITH ACUTE LEUKEMIA ABOVE 70 YEARS OF AGE: ON BEHALF OF THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT	Arnon Nagler	Received

380-P	BLOOD BAALC AND MN1 COPY NUMBER ASSESSMENT BY DIGITAL DROPLET PCR PRIOR TO ALLOGENEIC TRANSPLANTATION PREDICTS RELAPSE IN ACUTE MYELOID LEUKEMIA PATIENTS	Madlen Jentzsch	Received

381-P	THE USE OF BPX-501 DONOR T CELL INFUSION (WITH INDUCIBLE CASPASE 9 SUICIDE GENE) TOGETHER WITH HLA-HAPLOIDENTICAL STEM CELL TRANSPLANT TO TREAT CHILDREN WITH HEMOGLOBINOPATHIES AND ERYTHROID DISORDERS	Alice Bertaina	Received

382-P	EXCELLENT RESPONSE, LOW TRM AND GOOD SURVIVAL IN PATIENTS WITH THERAPY-REFRACTORY AGVHD AFTER TREATMENT WITH EQUIPOTENT MSCS OF A SERUM-FREE MSC-BANK GENERATED FROM POOLED BM-MNCS OF MULTIPLE DONORS	Peter Bader	Received

383-P	HIGHER PEAK TACROLIMUS CONCENTRATIONS AFTER ALLOGENEIC TRANSPLANTATION INCREASE THE RISK OF ENDOTHELIAL CELL DAMAGE COMPLICATIONS	Takanobu Morishita	Received

384-P	IMPACT OF CONDITIONING REGIMEN ON OUTCOMES OF T-REPLETE HAPLO-IDENTICAL TRANSPLANTATION FOR PATIENTS OVER 45 YEARS-OLD WITH AML: A STUDY ON BEHALF OF THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT	Daniela Nasso	Received

385-P	ROLE OF UPFRONT ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH AGGRESSIVE ADULT T-CELL LEUKEMIA-LYMPHOMA: A DECISION ANALYSIS	Shigeo Fuji	Received

387-P	INTERFERON-? IS EFFECTIVE FOR TREATMENT OF MINIMAL RESIDUAL DISEASE IN PATIENTS WITH ACUTE LEUKEMIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	Xiao-Dong Mo	Received

388-P	COMPARABLE LONG-TERM OUTCOME AFTER ALLOGENEIC STEM-CELL TRANSPLANTATION FOR OLDER PATIENTS (AGE =50 YEARS) WITH AML FROM SIBLING AND MATCHED UNRELATED DONORS. A REPORT ON BEHALF OF THE ALWP OF EBMT.	Avichai Shimoni	Received

389-P	IMPACT OF AZACITIDINE PRETREATMENT ON OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH HIGH-RISK MYELODYSPLASTIC SYNDROME	Jun Aoki	Received

390-P	LOW-DOSE DECITABINE IMPROVES PLATELET RECOVERY IN PATIENTS WITH ISOLATED THROMBOCYTOPENIA AFTER HSCT	Yue Han	Received

391-P	QUANTITATIVE PROTEOMICS OF PLASMA EXTRACELLULAR VESICLES TO IDENTIFY NOVEL BIOMARKERS OF CLINICAL SEVERITY FOR HBE/?-THALASSEMIC PATIENTS	Janejira Kittivorapart	Received

392-P	A SELECTIVE ORAL GLYT1 INHIBITOR IMPROVES ANEMIA IN A MOUSE MODEL OF BETA-THALASSEMIA	Lucia De Franceschi	Received

393-P	MAY MUTATIONS IN THE KLF1 GENE HAVE WORSENING EFFECTS ON THE BETA THALASSEMIA PHENOTYPE?	Michela Grosso	Received

394-P	SECONDARY SOLID TUMORS FOLLOWING HEMATOPOIETIC CELL TRANSPLANTATION FOR THALASSEMIA MAJOR	Antonella Meloni	Received

395-P	VALIDATING A NOVEL CAPILLARY ELECTROPHORESIS: THE MOST SUITABLE PLATFORM FOR THE NATIONAL NEWBORN SCREENING PROGRAM IN A REGION WITH HIGH PREVALENCE OF THALASSEMIA AND HEMOGLOBINOPATHIES	Thidarat Suksangpleng	Received

397-P	INCREASING INCIDENCE OF MALIGNACIES IN AGING THALASSEMIC PATIENTS: A SINGLE INSTITUTION´S LONGITUDINAL EXPERIENCE	Elpida Repousi	Received

398-P	SAFETY AND EFFICACY OF EARLY START WITH SUBOPTIMAL DOSE OF DEFERIPRONE IN MINIMALLY TRANSFUSED INFANTS WITH TRANSFUSION DEPENDENT THALASSEMIA: A RANDOMIZED TRIAL	Mohsen Elalfy	Received

399-P	LONGITUDINAL PROSPECTIVE MRI STUDY IN PEDIATRIC PATIENTS WITH THALASSEMIA MAJOR	Maddalena Casale	Received

400-P	LONG TERM FOLLOW-UP OF A COHORT OF WELL TREATED ?-THALASSEMIA MAJOR PATIENTS BY MULTI-ORGAN R2* MAGNETIC RESONANCE IMAGING	GianLuca Forni	Received

401-P	DEVELOPMENT OF HTLV-1 HYPERIMMUNE GLOBULINS AGAINST HTLV-1 INFECTION	Takuo Mizukami	Received

402-P	THE CONTAMINATION OF TUMOR CELLS IN THE APHERESIS MATERIAL DOES NOT PREDICT THE RESPONSE OF MULTIPLE MYELOMA PATIENTS TO AUTOLOGOUS TRANSPLANTATION	Maria Luisa Lozano	Received

403-P	EVALUATION OF THERAPEUTIC PLASMA EXCHANGE AT A TERTIARY LONDON HOSPITAL	Rachel Moll	Received

404-P	A COMPREHENSIVE PROTEOMICS STUDY ON PLATELET CONCENTRATES: PLATELET PROTEOME, STORAGE TIME AND MIRASOL PATHOGEN REDUCTION TECHNOLOGY	Laura Gutierrez	Received

405-P	USE OF A SURVEY TO ASSESS AND IMPROVE ADHERENCE TO UK BLOOD TRANSFUSION GUIDELINES IN A HOSPITAL SETTING	Dana Warcel	Received

406-P	SCREENING OF TRANSFUSION PRODUCTS FOR PRION DISEASES USING APTAMERS AND TUNABLE RESISTIVE PULSE SENSING	Matthew Healey	Received

506-P	T CELL EXHAUSTION CHARACTERIZED BY COMPROMISED MHC CLASS I AND II RESTRICTED CYTOTOXIC ACTIVITY ASSOCIATES WITH ACUTE B LYMPHOBLASTIC LEUKEMIA RELAPSE AFTER ALLO-HSCT	Long Liu	Received

507-P	RUXOLITINIB/NILOTINIB COTREATMENT BETTER INHIBITS LEUKEMIA-PROPAGATING CELLS IN PHILADELPHIA CHROMOSOME-POSITIVE ALL	Yuan Kong	Received

509-P	CD45RA- MEMORY T CELLS EXPRESSING AN NKG2D-CAR TARGET PEDIATRIC ACUTE LEUKEMIA	Lucia Fernandez	Received

510-P	A BILINEAL ACUTE LYMPHOBLASTIC LEUKEMIA ORIGINATING AT A COMMON LYMPHOID PROGENITOR	Africa Gonzalez-Murillo	Received

512-P	THERAPEUTIC TARGETING OF PRE-B CELL RECEPTOR SIGNALLING IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA	Ali Alhammer	Received

513-P	BMP-4 LEVELS IN CHILDHOOD B-ALL OF LOW-/INTERMEDIATE-RISK GROUPS IDENTIFY CHILDREN WITH POOR OUTCOME	Lidia Fernández-Sevilla	Received

514-P	TARGETING LOCALIZATION OF THE IL-7 RECEPTOR WITHIN LIPID RAFTS AS A THERAPEUTIC STRATEGY FOR T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA	Anne Buffière	Received

515-P	SYSTEMATIC MRI SCREENING IDENTIFIES EXTENSIVE ASYMPTOMATIC OSTEONECROTIC LESIONS IN ADOLESCENTS WITH ALL - FIRST INTERIM FINDINGS OF THE OPAL TRIAL	Michaela Kuhlen	Received

516-P	FINAL ANALYSIS OF A RANDOMIZED STUDY COMPARING PROPHYLACTIC AND MRD-TRIGGERED, PRE-EMPTIVE IMATINIB AFTER HSCT FOR PH+/BCR-ABL1 POSITIVE ALL: LONG-TERM PATIENT OUTCOME AND IMPLICATIONS OF MRD ANALYSIS	Fabian Lang	Received

518-P	UPDATED RESULTS OF A PHASE II STUDY OF HYPER-CVAD PLUS PONATINIB AS FRONTLINE THERAPY FOR ADULTS WITH PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA	Nicholas Short	Received

520-P	A PHASE II STUDY WITH A SEQUENTIAL CLOFARABINE-CYCLOPHOSPHAMIDE COMBINATION SCHEDULE AS SALVAGE THERAPY FOR REFRACTORY AND RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA (R/R ALL) IN ADULT PATIENTS	Renato Bassan	Received

526-P	DESIGNING THE NEXT GENERATION CD33-TARGETING ADC: IMGN779, SELECTED FOR POTENCY, NOVEL MECHANISM AND PRECLINICAL TOLERABILITY, WITH HIGH ACTIVITY IN DISSEMINATED AML MODELS AND MULTI-DOSE REGIMENS	Sharlene Adams	Received

528-P	PKC EPSILON SUPPORTS ACUTE MYELOID LEUKEMIA BY MAINTAINING MITOCHONDRIAL REDOX HOMEOSTASIS.	Daniela Di Marcantonio	Received

530-P	ROLE OF SHP2 IN A MOUSE MODEL OF AML CARRYING FLT3-ITD ALONG WITH LOSS OF TET2	Ruchi Pandey	Received

531-P	CLUSTER REGULATION OF RUNX FAMILY BY "GENE SWITCH" TRIGGERS A PROFOUND TUMOR REGRESSION OF DIVERSE ORIGINS.	Ken Morita	Received

532-P	PHOSPHOPROTEOMICS AND MASS CYTOMETRY SIGNATURES OF PRIMARY AML CELL DIFFERENTIATION ARE ASSOCIATED WITH SENSITIVITY TO KINASE INHIBITORS	Pedro Casado-Izquierdo	Received

534-P	GFI1B – A NOVEL ONCOSUPPRESSOR WHICH RESTRICTS NUMBER OF LEUKEMIC STEM CELLS	Aniththa Thivakaran	Received

535-P	VARIANT ALLELE FREQUENCY KINETICS OF TYROSINE KINASE GENE MUTATIONS IN CORE-BINDING FACTOR ACUTE MYELOID LEUKEMIA (CBF-AML) UNDER TREATMENT WITH AND WITHOUT DASATINIB	Mridul Agrawal	Received

536-P	P38? MAPK INTERACTS WITH SET REGULATING ITS INHIBITORY EFFECT ON PP2A ACTIVITY IN ACUTE MYELOID LEUKEMIA	Elena Arriazu	Received

539-P	EXPLORING THE IMPACT OF LOSS OF FUNCTION STAG2 MUTATIONS ON CHROMATIN ARCHITETCURE IN MDS/AML	James Smith	Received

540-P	NEXT GENERATION SEQUENCING TECHNIQUES REVEAL MOLECULAR MECHANISMS OF MYB REGULATION AND FUNCTION IN MLL-AF9 LEUKEMIA	I-Jun Lau	Received

542-P	TARGETED COMBINATION THERAPY WITH CDK4/6 INHIBITOR PALBOCICLIB IN AML	Iris Uras	Received

543-P	CANNABINOIDS DERIVATIVES MODIFY THE PATTERN OF SPHINGOLIPIDS IN ACUTE MYELOID LEUKEMIA CELLS AND PRODUCE A POTENT ANTI-LEUKEMIC EFFECT.	Mayte Medrano	Received

544-P	PROFILING THE MUTATIONAL LANDSCAPE OF ACUTE MYELOID LEUKEMIA AT RELAPSE AFTER CHEMOTHERAPY AND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION.	Elisa Sala	Received

546-P	AML PATIENTS AGED =75 YEARS ENROLLED INTO AMLCG TRIALS: DO GENETIC ALTERATIONS IMPACT CLINICAL OUTCOME IN VERY OLD, INTENSIVELY TREATED PATIENTS?	Victoria Prassek	Received

548-P	BST 236, A NOVEL CYTARABINE PRO-DRUG ALLOW, FOR THE FIRST TIME, THE DELIVERY OF HIGH CYTARABINE DOSES FOR OLDER OR UNFIT PATIENTS WITH ACUTE LEUKEMIA. RESULTS OF AN ONGOING PHASE I/IIA STUDY	Tsila Zuckerman	Received

549-P	FEASIBILITY AND BENEFIT OF TARGETED RNA SEQUENCING FOR THE DETECTION OF RECURRENT FUSION TRANSCRIPTS AND THE IDENTIFICATION OF NOVEL FUSION TRANSCRIPTS IN MYELOID MALIGNANCIES	Claudia Haferlach	Received

550-P	COMPREHENSIVE MOLECULAR ANALYSIS OF ADULT MIXED PHENOTYPE ACUTE LEUKEMIA (MPAL)	Kiyomi Morita	Received

552-P	VARIANT FLT3 MUTATIONS CAN BE ERADICATED BY CYTARABINE/ANTHRACYCLINE/CRENOLANIB INDUCTION IN ADULT PATIENTS WITH NEWLY DIAGNOSED FLT3 (ITD/TKD) MUTANT AML	Eunice Wang	Received

553-P	PATIENTS WITH ACUTE MYELOID LEUKEMIA WHO HAVE MUTATIONS IN IDH1 OR IDH2 RESPOND WELL TO INDUCTION CHEMOTHERAPY WITH "7+3" DESPITE THE PRESENCE OF COMPLEX KARYOTYPE OR FLT3-ITD	Medhavi Gupta	Received

554-P	VALIDATION OF PRECISION MEDICINE TEST FOR ACUTE MYELOID LEUKEMIA IN AN OBSERVATIONAL CLINICAL TRIAL.	Joan Ballesteros	Received

555-P	RESPONSE-ADAPTED AZACITIDINE AND INDUCTION CHEMOTHERAPY IN PATIENTS > 60 YEARS OLD WITH NEWLY DIAGNOSED AML ELIGIBLE FOR CHEMOTHERAPY: RESULTS OF THE DRKS00004519 STUDY OF THE EAST GERMAN STUDY GROUP	Nadja Jaekel	Received

556-P	OVERALL SURVIVAL WITH CPX-351 VERSUS 7+3 IN OLDER ADULTS WITH NEWLY DIAGNOSED, THERAPY-RELATED ACUTE MYELOID LEUKEMIA: SUBGROUP ANALYSIS OF A PHASE 3 STUDY	Jeffrey Lancet	Received

557-P	HYPERFERRITINEMIA IS AN INDEPENDENT POOR PROGNOSTIC FACTOR IN ACUTE MYELOID LEUKEMIA	Sarah Bertoli	Received

559-P	PROGNOSTIC VALUE OF EARLY WT 1 RESPONSE IN AML PATIENTS UNDERGOING INTENSIVE CHEMOTHERAPY	Sigrid Machherndl-Spandl	Received

565-P	WHOLE BODY DIFFUSION-WEIGHTED MAGNETIC RESONANCE IMAGING IS A GOOD PREDICTOR OF TREATMENT OUTCOME AFTER ONE CYCLE OF IMMUNOCHEMOTHERAPY IN AGGRESSIVE LYMPHOMA	Katja De Paepe	Received

567-P	PREVALENCE AND PROGNOSTIC VALUE OF MYD88 AND CD79B MUTATIONS IN IMMUNE-PRIVILEGED SITE AND (EXTRA)NODAL DLBCLS.	Joost Vermaat	Received

568-P	HIV-INFECTED PATIENTS WITH RELAPSED NON-HODGKIN LYMPHOMA (NHL) OR HODGKIN LYMPHOMA (HL): RESULTS FROM THE GERMAN HIV-RELATED LYMPHOMA COHORT STUDY	Marcus Hentrich	Received

569-P	RISK STRATIFICATION BASED ON NCCN-IPI AT THE TIME OF DIAGNOSIS IN COMBINATION WITH POST-TREATMENT PET-CT SCAN FOR THE TREATMENT OF NODAL PERIPHERAL T-CELL LYMPHOMA	Deok-Hwan Yang	Received

570-P	LONG-TERM EFFICACY AND SAFETY OF CRIZOTINIB IN RELAPSED ALK POSITIVE LYMPHOMA PATIENTS: CLINICAL AND BIOLOGICAL CORRELATES.	Francesca Farina	Received

571-P	PRELIMINARY RESULTS FROM AN OPEN-LABEL, PHASE II STUDY OF TIPIFARNIB IN RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA.	Thomas Witzig	Received

572-P	BAM CONDITIONING BEFORE AUTOLOGOUS STEM CELL TRANSPLANTATION FOR LYMPHOMA: A RETROSPECTIVE STUDY ON BEHALF OF THE FRANCOPHONE SOCIETY OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY (SFGM-TC).	Jérôme Cornillon	Received

573-P	ANALYSIS OF MICRORNAOME, PROTEOME AND METABOLOME OF EXOSOMES FROM PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA	Irene Martínez	Received

575-P	SEVERE CHRONIC NEUTROPENIA: THE ROLE OF PRIMARY IMMUNODEFICIENCY AS CAUSATIVE AGENTS . A SINGLE CENTER DATA	Francesca Fioredda	Received

576-P	TREATMENT WITH HORSE-DERIVED ANTI-THYMOCYTE GLOBULIN LEADS TO ENDURING HEMATOLOGICAL RESPONSES AND A 1.5-YEAR SURVIVAL PROBABILITY OF 87% IN ADULT ACQUIRED APLASTIC ANEMIA PATIENTS IN THE NETHERLANDS	Stijn Halkes	Received

577-P	IMMUNE RECONSTITUTION IN PATIENTS WITH ACQUIRED SEVERE APLASTIC ANEMIA AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION	Xuying Pei	Received

578-P	DEVELOPMENT OF A SCREENING AND DIAGNOSTIC ALGORITHM FOR PAROXYSMAL NOCTURNAL HEMOGLOBINURIA USING A MODIFIED DELPHI PANEL METHODOLOGY	Alexander Röth	Received

579-P	DIAMOND-BLACKFAN ANEMIA IN THE NETHERLANDS: AN OVERVIEW OF CLINICAL CHARACTERISTICS AND UNDERLYING MOLECULAR DEFECTS.	Birgit Van Dooijeweert	Received

580-P	NEXT GENERATION SEQUENCING IN BONE MARROW FAILURE SYNDROMES	Eva Galvez	Received

581-P	APLASTIC ANEMIA PATIENTS WITH MONOCYTE-DOMINANT PNH CLONES HAVE A UNIQUE PRESENTATION AND ARE LESS RESPONSIVE TO IMMUNOSUPPRESSIVE THERAPY	Emilie Nevill	Received

582-P	RESPONSE TO ANTI-THYMOCYTE GLOBULIN (ATG) IN PATIENTS WITH APLASTIC ANEMIA (AA): A SINGLE-CENTRE EXPERIENCE OVER THE LAST 28 YEARS	Maren Oelmüller	Received

583-P	NOTCH1 MUTATED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS ARE CHARACTERIZED BY A MYC-RELATED OVEREXPRESSION OF NUCLEOPHOSMIN-1 AND RIBOSOME ASSOCIATED COMPONENTS	Federico Pozzo	Received

584-P	CLL-LIKE B-CELL CLONES FROM MBLLO INDIVIDUALS PERSIST AT INCREASED COUNTS AFTER SEVEN YEARS OF FOLLOW-UP.	Ignacio Criado	Received

585-P	NUCLEAR LAMINA REGULATES SOMATIC HYPERMUTATION AND PROGRESSION OF B CELL MALIGNANCIES	Andrejs Braun	Received

586-P	MICROENVIRONMENT REGULATION OF PROGRAMMED DEATH-1 (PD1) RECEPTOR AND ITS LIGANDS PDL1 AND PDL2 IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)	Fortunato Morabito	Received

587-P	IL-4 INCREASES EXPRESSION OF POSITIVE REGULATORS OF BCR SIGNALLING IN CLL WHICH CAN BE OVERCOME BY CERDULATINIB	Matthew Blunt	Received

588-P	INSIDE-OUT VLA-4 INTEGRIN ACTIVATION IS MAINTAINED IN IBRUTINIB-TREATED CHRONIC LYMPHOCYTIC LEUKEMIA EXPRESSING CD49D: CLINICAL RELEVANCE	Erika Tissino	Received

589-P	IBRUTINIB RESULTS IN REDUCTION OF PHOSPHORYLATION OF MULTIPLE KINASES IN THE B-CELL RECEPTOR PATHWAY IN CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL): RESULTS OF THE BLOODWISE TAP ICICLLE STUDY	Talha Munir	Received

590-P	EVALUATION OF COMBINATIONAL THERAPIES FOR RELAPSED/REFRACTORY CLL WITH MUTATED P53	Sean Post	Received

591-P	THE DNA REPLICATION PATHWAY HAS POTENTIAL PREDICTIVE VALUE FOR TKI RESPONSE AND THERAPEUTIC INTERVENTION IN CHRONIC MYELOID LEUKAEMIA	Krishna Yalla	Received

592-P	SIGNAL TRANSDUCING ADAPTOR PROTEIN-1 (STAP-1) MAINTAINS CHRONIC MYELOID LEUKEMIC STEM CELLS	Jun Toda	Received

593-P	TELOMERE SHORTENING IN CD34+38- BCR-ABL POSITIVE BONE MARROW CELLS FROM NEWLY DIAGNOSED PATIENTS WITH CML CORRELATES WITH THE CLONE SIZE OF THE LEUKEMIC STEM CELL COMPARTMENT	Anne-Sophie Bouillon	Received

595-P	INCREASED INDOLEAMINE 2,3-DIOXYGENASE (IDO1) ACTIVITY IN EARLY CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA (CML-CP) IS REDUCED BY NILOTINIB THERAPY AND PREDICTS MOLECULAR RESPONSE	Sieghart Sopper	Received

596-P	BCR-ABL1 COMPOUND MUTANTS DISPLAY DIFFERENTIAL AND DOSE-DEPENDENT RESPONSES TO PONATINIB	Konstantin Byrgazov	Received

597-P	IS THERE EFFECTIVE IMMUNE SURVEILLANCE AGAINST CHRONIC MYELOID LEUKAEMIA? NO.	Robert Gale	Received

598-P	MUTATIONAL ANALYSIS IN BCR-ABL1 POSITIVE LEUKEMIA BY DEEP SEQUENCING BASED ON NANOPORE MINION TECHNOLOGY	Francesco Albano	Received

599-P	THE AUTOMATED MOLECULAR TECHNIQUE "ULTRA" ALLOWS A SENSITIVE AND ACCURATE BCR-ABL1 QUANTIFICATION IN PATIENTS AFFECTED BY CHRONIC MYELOID LEUKEMIA.	Sara Galimberti	Received

601-P	DURABLE TREATMENT-FREE REMISSION (TFR) FOLLOWING FRONTLINE NILOTINIB (NIL) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): ENESTFREEDOM 96-WK UPDATE	David Ross	Received

602-P	RESPONSE DIFFERENCES IN THE BCR-ABL1 E13A2 AND E14A2 VARIANTS MAY BE A TECHNICAL QPCR ARTIFACT	Lasse Kjaer	Received

603-P	5-YR RESULTS FROM THE PIVOTAL PHASE 2 PONATINIB PACE TRIAL: EFFICACY, SAFETY AND LANDMARK ANALYSIS IN HEAVILY PRETREATED PATIENTS (PTS) WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML)	Jorge Cortes	Received

604-P	LONG-TERM FOLLOW-UP IN VERY ELDERLY PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH IMATINIB FRONTLINE	Isabella Capodanno	Received

605-P	IMPACT OF ARTERIAL THROMBOTIC EVENTS ON THE LONG-TERM OUTCOME OF CHRONIC MYELOID LEUKEMIA (CML) PATIENTS TREATED IN FIRST-LINE WITH NILOTINIB: AN ANALYSIS OF THE GIMEMA CML WORKING PARTY	Gabriele Gugliotta	Received

606-P	ASSESSMENT OF CHRONIC RENAL INJURY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE RECEIVING TYROSINE KINASE INHIBITORS	Qian Jiang	Received

607-P	COMPARATIVE MONITORING OF MINIMAL RESIDUAL DISEASE (MRD) BY QPCR AND DIGITAL-PCR (DPCR) IN CHRONIC MYELOID LEUKEMIA PATIENTS ACHIEVING MAJOR OR DEEP MOLECULAR RESPONSE WITH TIROSIN-KINASE INHIBITORS	Simona Bernardi	Received

608-P	OUTCOME OF BLAST PHASE CHRONIC MYELOID LEUKEMIA (CML-BP) IN THE TYROSINE KINASE INHIBITOR ERA	Chetasi Talati	Received

609-P	EFFICACY OF SWITCHING TO DASATINIB IN CHRONIC MYELOID PATIENTS WITH LATE WARNING RESPONSES TO IMATINIB. STUDY OF THE ASSOCIATION OF RESPONSE TO DASATINIB TO IMMUNOLOGIC STATUS	Juan Luis Steegmann	Received

610-P	GENETIC PREDICTION OF INSULIN RESISTANCE IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH NILOTINIB	Giovanni Caocci	Received

611-P	THE EUROPE AGAINST CANCER PROTOCOL FOR BCR-ABL P210 TRANSCRIPT MEASUREMENT MAY OVERESTIMATE RESULTS FOR E13A2 VARIANT	Michal Gniot	Received

612-P	ESTABLISHMENT OF IN VIVO AND IN VITRO MODEL OF X-LINKED SIDEROBLASTIC ANEMIA	Kei Saito	Received

613-P	BENDAMUSTINE AND RITUXIMAB COMBINATION THERAPY FOR COLD AGGLUTININ DISEASE: RESULTS OF A PROSPECTIVE NORDIC TRIAL.	Sigbjørn Berentsen	Received

615-P	IDENTIFICATION OF NEW PATHOGENIC MUTATIONS IN PATIENTS WITH RED BLOOD CELL MEMBRANE DISORDERS USING NEXT-GENERATION SEQUENCING	Maria Del Mar Mañu Pereira	Received

616-P	CLINICAL FOLLOW-UP OF 378 PATIENTS WITH AUTOIMMUNE HEMOLYTIC ANEMIA: PROGNOSTIC IMPACT OF HEMOGLOBIN LEVELS, AUTOANTIBODY CLASS, AND RETICULOCYTOPENIA AT ONSET ON THE RELAPSE RISK AND OUTCOME	Bruno Fattizzo	Received

618-P	USE OF PEGYLATED-CARBOXYHEMOGLOBIN BOVINE FOR THE TREATMENT OF SICKLE CELL DISEASE ASSOCIATED LEG ULCERS: RESULTS FROM A PHASE 2 SAFETY STUDY	Hemant Misra	Received

619-P	NON-RENAL DETERMINANTS OF ENDOGENOUS ERYTHROPOIETIN LEVELS IN SICKLE CELL DISEASE	Kate Gardner	Received

623-P	NHEJ-BASED GENE EDITING: A NOVEL GENE THERAPY APPROACH IN FANCONI ANEMIA HEMATOPOIETIC STEM AND PROGENITOR CELLS	Francisco Roman-Rodriguez	Received

624-P	NOVEL, ENHANCED AND DUAL TARGETING CAR INVARIANT NKT CELL-BASED IMMUNOTHERAPY FOR CD1D+ B CELL MALIGNANCIES	Antonia Rotolo	Received

625-P	A NOVEL CHIMERIC ANTIGEN RECEPTOR ENDOWS T CELLS WITH NK CELL-LIKE SPECIFICITY AND ATTACKS A WIDE RANGE OF HEMATOLOGICAL MALIGNANCIES AND CANCERS	Yasushi Kasahara	Received

627-P	PRECLINICAL TESTING OF ADOPTIVE T-CELL RECEPTOR GENE TRANSFER IN COMBINATION WITH CHECKPOINT INHIBITORS AS A NOVEL THERAPY FOR MULTIPLE MYELOMA	Hakim Echchannaoui	Received

630-P	SPECIFIC TARGETING OF ACUTE MYELOID LEUKEMIA BY THE USE OF ENGINEERED CIK (CYTOKINE-INDUCED KILLER) CELLS EXPRESSING THE ANTI-CD33 CHIMERIC ANTIGEN RECEPTOR (CAR).	Maria Rotiroti	Received

632-P	A SINGLE INSTITUTIONAL EXPERIENCE OF 261 PATIENTS WITH LARGE GRANULAR LYMPHOCYTIC LEUKEMIA	Magali Van den Bergh	Received

633-P	ONGOING PHASE 1/2 STUDY OF INCB050465, A SELECTIVE PI3K-DELTA INHIBITOR, FOR THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY B-CELL MALIGNANCIES (CITADEL-101)	Andres Forero-Torres	Received

634-P	PHASE IIIB RANDOMIZED STUDY OF LENALIDOMIDE PLUS RITUXIMAB (R2) FOLLOWED BY LENALIDOMIDE VS. RITUXIMAB MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY NHL: ANALYSIS OF FOLLICULAR LYMPHOMA PATIENTS	John Burke	Received

635-P	A DOUBLE-BLIND, RANDOMIZED PHASE 3 STUDY TO COMPARE EFFICACY AND SAFETY OF CT-P10 TO INNOVATOR RITUXIMAB IN COMBINATION WITH CVP IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED FOLLICULAR LYMPHOMA	Michinori Ogura	Received

636-P	DURABLE DISEASE CONTROL OF EARLY MYCOSIS FUNGOIDES PATIENTS TREATED WITH LOW-DOSE INTERFERON-ALPHA2B AND PUVA	Serena Rupoli	Received

639-P	CLONAL B-CELL LYMPHOCYTOSIS OF MARGINAL ZONE ORIGIN (CBL-MZ): A PROSPECTIVE REGISTRATIONAL STUDY ON 96 CASES	Christina Kalpadakis	Received

640-P	SAFETY OF SUBCUTANEOUS ADMINISTRATION OF RITUXIMAB DURING THE FIRST-LINE TREATMENT OF PATIENTS WITH NON-HODGKIN LYMPHOMA: THE MABRELLA STUDY	Carlos Panizo	Received

642-P	MICAFUNGIN VERSUS LIPOSOMAL AMPHOTERICIN B FOR EMPIRICAL ANTIFUNGAL THERAPY IN FEBRILE NEUTROPENIC PATIENTS WITH HEMATOLOGICAL MALIGNANCIES: A RANDOMIZED CONTROLLED TRIAL	Tatsuo Oyake	Received

643-P	ANTIFUNGAL DRUGS INFLUENCE NEUTROPHIL EFFECTOR FUNCTIONS IN VITRO AND MODULATE PULMONARY DAMAGE IN INVASIVE ASPERGILLOSIS	Daniel Teschner	Received

644-P	CHARACTERISTICS AND OUTCOME OF PULMONARY INFILTRATES IN ACUTE LEUKEMIA CLASSIFIED ACCORDING TO EORTC/MSG CRITERIA OF INVASIVE FUNGAL INFECTION: A PROSPECTIVE STUDY BY THE RETE EMATOLOGICA LOMBARDA	Chiara Cattaneo	Received

645-P	ANTIFUNGAL PROPHYLAXIS WITH CD101 IN IMMUNOSUPPRESSED MOUSE MODELS OF CANDIDIASIS, ASPERGILLOSIS, AND PNEUMOCYSTIS PNEUMONIA (PCP)	Voon Ong	Received

646-P	SURGICAL MANAGEMENT OF INVASIVE FUNGAL INFECTIONS IN ADULT LEUKAEMIA PATIENTS – EXPERIENCE FROM A LARGE TERTIARY CENTRE IN SOUTH-EAST ASIA	Chandramouli Nagarajan	Received

647-P	INFECTIONS IN MULTIPLE MYELOMA ARE FREQUENT AND PREDOMINANTLY CAUSED BY BACTERIA: RESULTS OF A 12-YEAR SURVEY FROM A SINGLE CENTER	Marie Von Lilienfeld-Toal	Received

648-P	HUMAN L-FICOLIN POLYMORPHISMS CONTRIBUTE TO SUSCEPTIBILITY TO INFECTIONS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA	Ulf Schnetzke	Received

649-P	PREDICTIVE FACTORS OF RESPONSE TO EPOETIN THETA IN CHEMOTHERAPY-INDUCED ANEMIA: A FRENCH MULTICENTER OBSERVATIONAL STUDY (PIVOINE).	Philippe RODON	Received

650-P	TIMING OF DEFIBROTIDE INITIATION POST-DIAGNOSIS OF HEPATIC VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME AFTER PRIMARY CHEMOTHERAPY: EXPLORATORY ANALYSIS OF AN EXPANDED-ACCESS PROTOCOL	Paul Richardson	Received

651-P	ADAMTS-13 REGULATES NEUTROPHIL RECRUITMENT IN A MOUSE MODEL OF INVASIVE PULMONARY ASPERGILLOSIS	Astrid Hasibeder	Received

652-P	IDENTIFICATION OF THE SPECIFIC HEMATOPOIETIC STEM CELL POPULATIONS RESPONSIBLE FOR FAILURE TO HYPOMETHYLATING AGENTS IN MYELODYSPLASTIC SYNDROMES	Irene Gañán-Gómez	Received

655-P	CLONAL EVOLUTION OF STAG2 AND NRAS DURING PROGRESSION FROM MDS TO SAML ASSESSED BY WHOLE-EXOME AND TARGETED-DEEP SEQUENCING	Marta Martín-Izquierdo	Received

656-P	PROGRESSION OF MDS TO AML FEATURES GAIN OF SINGLE DRIVER MUTATIONS WITH CONSEQUENT CHANGES IN CLONAL COMPOSITION AND OCCURRENCE OF MULTIPLE CLONES WITH MUTATIONS IN IDENTICAL GENES	Juliane Stosch	Received

657-P	PRECLINICAL MODELING OF MYELODYSPLASTIC SYNDROMES	Kevin Rouault-Pierre	Received

658-P	MYELODYSPLASTIC SYNDROMES WITH IRON OVERLOAD ARE CHARACTERIZED BY A SWITCH FROM OXIDATIVE PHOSPHORYLATION TO GLYCOLYSIS AND THIS DEFECT IS PARTIALLY RESTORED BY IRON CHELATION. A FISM STUDY	Daniela Cilloni	Received

659-P	V-SET AND IMMUNOGLOBULIN DOMAIN-CONTAINING 4 (VSIG4) EXPRESSED ON MONOCYTES INCLUDING TUMOR-ASSOCIATED MACROPHAGES SUPPRESSED ANTITUMOR IMMUNE RESPONSES IN MYELODYSPLASTIC SYNDROMES	Yasuko Kuribayashi-Hamada	Received

660-P	TRANSCRIPTOME ASSESSMENT OF DNA REPAIR GENES IN CHRONIC MYELOMONOCYTIC LEUKEMIA: SYNTHETIC LETHALITY TARGETS	Ana María Hurtado López	Received

661-P	DIFFERENTIAL DIAGNOSIS BETWEEN MYELODYSPLASTIC SYNDROMES AND NON-CLONAL CYTOPENIAS BY FLOW CYTOMETRY ANALYSIS USING A MYELOID MATURATION DATABASE	MTeresa Cedena	Received

663-P	EPIGENETIC DRUG TREATMENT GLOBALLY INDUCES CRYPTIC TRANSCRIPTION START SITES ENCODED IN LONG TERMINAL REPEATS (LTRS)	Michael Daskalakis	Received

665-P	IMPACT OF MARROW COMPLETE RESPONSE IN THE NATURAL HISTORY OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) AND CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) TREATED WITH HYPOMETHYLATING AGENTS	Ana Alfonso Pierola	Received

667-P	RATE AND CAUSES OF 5-AZACYTIDINE DISCONTINUATION AND SUBSEQUENT THERAPEUTIC OPTIONS IN 418 MDS PATIENTS FROM THE ITALIAN MDS REGISTRY OF FONDAZIONE ITALIANA SINDROMI MIELODISPLASTICHE (FISM)	Marino Clavio	Received

668-P	COMBINATION OF DEEP PHENOTYPING AND TARGETED NEXT GENERATION SEQUENCING AS A DIAGNOSTIC TOOL IN CHILDREN WITH SUSPECTED MDS	Eleni Louka	Received

669-P	OUTCOMES IN PATIENTS ALLOCATED TO NO-ASCT BASED ON DEPTH OF RESPONSE: INITIAL RESULTS OF A PHASE 2 TRIAL ASSESSING THE IMPACT OF MINIMAL RESIDUAL DISEASE (MRD) IN PATIENTS WITH DEFERRED ASCT (PADIMAC)	Kwee Yong	Received

670-P	PROPORTION AND COMPOSITION OF BONE MARROW LYMPHOCYTE POOL AT BASELINE CORRELATES WITH OUTCOME IN MM PATIENTS AFTER RVD AND ASCT	Sini Luoma	Received

671-P	VALUE OF THE 18F-FDG PET-CT IN THE IDENTIFYING BONE INVOLVEMENT EITHER AT DIAGNOSIS OR DURING FOLLOW-UP OF PATIENTS AFFECTED BY MULTIPLE MYELOMA.	Sara Galimberti	Received

673-P	PROGNOSTIC SIGNIFICANCE OF CLONAL CIRCULATING PLASMA CELLS BY MULTI-PARAMETRIC FLOW CYTOMETRY IN PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION	Surbhi Sidana	Received

674-P	RENAL IMPAIRMENT IN MYELOMA - PATIENT CHARACTERISTICS, TREATMENT MODALITIES, STEM CELL TRANSPLANT & OUTCOMES FROM THE AUSTRALIAN AND NEW ZEALAND MYELOMA REGISTRY	Joy Ho	Received

676-P	AN OPEN-LABEL, PHASE 1B STUDY (MMY1001) OF DARATUMUMAB COMBINED WITH CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (KRD) IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (MM)	Saad Usmani	Received

677-P	GENE EXPRESSION CLASSIFIER EMC92/SKY92 AND REVISED ISS ROBUSTLY IDENTIFY HIGH-RISK MULTIPLE MYELOMA IN ELDERLY PATIENTS OF THE HOVON-87/NMSG-18 STUDY	Rowan Kuiper	Received

678-P	MULTIPLE MYELOMA AND COMORBIDITY: A POPULATION-BASED STUDY	Ingigerdur Solveig Sverrisdottir	Received

679-P	DETECTION OF NEW EMERGING CLONES DURING TREATMENT BY NGS ALLOWS A BETTER RISK PREDICTION ON MULTIPLE MYELOMA PATIENTS	Beatriz Sanchez-Vega	Received

680-P	FINAL RESULTS OF PHASE (PH) 1/2 STUDY OF CARFILZOMIB, POMALIDOMIDE, AND DEXAMETHASONE (KPD) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): A MULTI-CENTER MMRC STUDY	Andrzej Jakubowiak	Received

681-P	PANOBINOSTAT INDUCES CD38 UPREGULATION AND AUGMENTSTHE ANTI-MYELOMA EFFICACY OF DARATUMUMAB	Estefania Garcia-Guerrero	Received

683-P	THE IMPACT OF THE INTRODUCTION OF BORTEZOMIB ON DIALYSIS INDEPENDENCE IN MULTIPLE MYELOMA PATIENTS WITH RENAL FAILURE: A NATIONWIDE DUTCH POPULATION-BASED STUDY	Berdien Oortgiesen	Received

684-P	TREATMENT WITH POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA AND LIGHT CHAIN (AL) AMYLOIDOSIS	Paolo Milani	Received

685-P	MYOCARDIAL UPTAKE OF 99MTC-DPD IN PATIENTS WITH AL AMYLOIDOSIS	Carlos De Miguel	Received

686-P	WHEN PERFORMANCE OF CYTOGENETICS MATTERS: A POPULATION-BASED STUDY IN THE NETHERLANDS ON NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS	Mirian Brink	Received

687-P	AN UPDATED ADJUSTED COMPARISON SUGGESTS DARATUMUMAB IS ASSOCIATED WITH PROLONGED SURVIVAL COMPARED WITH STANDARD OF CARE THERAPIES IN HEAVILY PRE-TREATED AND HIGH REFRACTORY MULTIPLE MYELOMA PATIENTS	Shaji Kumar	Received

688-P	PREDICTORS OF EARLY DEATH RELATED TO ACTIVE MULTIPLE MYELOMA IN ELDERLY PATIENTS RECEIVING OPTIMIZED FRONTLINE TREATMENT COMBINATIONS	Paula Rodriguez Otero	Received

689-P	MPL ACTIVATION DIRECTLY INDUCES FIBROCYTE DIFFERENTIATION TO CAUSE MYELOFIBROSIS	Takaaki Maekawa	Received

690-P	ENGRAFTMENT OF PRIMARY MYELOFIBROSIS BONE MARROW-DERIVED CD14+ MONOCYTES IN NOD-SCID-? MICE	Taghi Manshouri	Received

691-P	ESTABLISHMENT OF AN IN VITRO MODEL FOR THE SKEWED MEGAKARYOPOIESIS BY CALRETICULIN MUTATION IN HUMAN CELLS	Hiraku Takei	Received

692-P	QUANTITATIVE PROTEOME HETEROGENEITY IN MYELOPROLIFERATIVE NEOPLASM SUBTYPES AND ASSOCIATION WITH JAK2 MUTATION STATUS	Nuria Yuste	Received

693-P	THE NOVEL SWITCH CONTROL INHIBITOR DCC-2618 COUNTERACTS GROWTH AND SURVIVAL OF VARIOUS NEOPLASTIC CELLS, INCLUDING MAST CELLS, EOSINOPHILS, AND MONOCYTES, IN PATIENTS WITH SYSTEMIC MASTOCYTOSIS	Mathias Schneeweiss	Received

694-P	DISTRIBUTION OF MUTATIONS IN DRIVER AND NON-DRIVER GENES ACCORDING TO CLONAL HEMATOPOIESIS IN ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA	Alicia Senín	Received

695-P	RUXOLITINIB/NILOTINIB/PREDNISOLONE COMBINATION: A PROMISING NOVEL TREATMENT FOR MYELOFIBROSIS	Joaquín Martínez-López	Received

696-P	INTERLABORATORY ASSESSMENT OF MUTATION DETECTION IN MYELOID MALIGNANCIES BY TARGETED NEXT-GENERATION SEQUENCING	Concepción Fernández-Rodríguez	Received

697-P	METHYLATION AGE IN MPN PATIENTS AS A CORRELATE FOR DISEASE STATUS, ALLELE BURDEN AND THERAPEUTIC RESPONSE	Suzanne McPherson	Received

702-P	SAFETY AND EFFICACY OF RUXOLITINIB (RUX) IN ELDERLY PATIENTS (= 75 YEARS) WITH MYELOFIBROSIS (MF): AN ANALYSIS FROM THE PHASE 3B, EXPANDED-ACCESS JUMP STUDY	Pia Raanani	Received

703-P	PROGNOSTIC RISK MODELS FOR TRANSPLANT DECISION-MAKING IN MYELOFIBROSIS	Juan Carlos Hernández-Boluda	Received

704-P	LEUKEMIC TRANSFORMATION AND SECOND CANCERS IN 3649 HIGH RISK ET PATIENTS IN THE EXELS STUDY	Gunnar Birgegård	Received

705-P	EPIDEMIOLOGY, OUTCOME AND RISK FACTORS FOR INFECTIOUS COMPLICATIONS IN MF PATIENTS RECEIVING RUXOLITINIB. A MULTICENTER STUDY ON 373 PATIENTS	Nicola Polverelli	Received

706-P	TREATMENT AND MANAGEMENT OF PATIENTS WITH MPNS—FINDINGS FROM THE INTERNATIONAL MPN LANDMARK SURVEY	Steffen Koschmieder	Received

709-P	MASITINIB FOR TREATMENT OF SEVERELY SYMPTOMATIC INDOLENT SYSTEMIC MASTOCYTOSIS: ADDITIONAL EFFICACY ANALYSES FROM THE RANDOMIZED, PLACEBO-CONTROLLED, PHASE 3 STUDY	Olivier Hermine	Received

710-P	THERAPY RESPONSE AND LONG-TERM OUTCOME OF 71 ADULT PATIENTS WITH HEMATOLOGICAL MALIGNANCY-ASSOCIATED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS: A SINGLE INSTITUTION EXPERIENCE	Maciej Machaczka	Received

712-P	SEQUENCING OF THE HYPOXIA PATHWAY GENES IN PATIENTS WITH CONGENITAL ERYTHROCYTOSES BY NEXT GENERATION SEQUENCING	Francois Girodon	Received

713-P	CHARACTERIZATION OF CD34+ HEMATOPOIETIC PRECURSORS IN INDOLENT SYSTEMIC MASTOCYTOSIS AND THEIR POTENTIAL ROLE IN EARLY DISSEMINATION OF THE DISEASE.	Andrea Mayado	Received

714-P	MONOALLELIC VARIANTS IN GENES RELATED TO FAMILIAL HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS: REPORT FROM THE ITALIAN REGISTRY	Laura Vinas	Received

716-P	NEUROLOGICAL INVOLVEMENT IN EVANS SYNDROME AND CHRONIC HEMOLYTIC AUTOIMMUNE ANEMIA OF CHILDREN: DESCRIPTION, EVOLUTION AND GENETICS	Thomas Pincez	Received

717-P	AUTOIMMUNE NEUTROPENIA OF CHILDHOOD SECONDARY TO OTHER AUTOIMMUNE DISORDERS: DATA FROM THE ITALIAN NEUTROPENIA REGISTRY	Piero Farruggia	Received

718-P	PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT DURING PREGNANCY	Maria Vinogradova	Received

719-P	LONG-TERM RESPONSE TO ORAL ELIGLUSTAT IN TREATMENT-NAÏVE ADULTS WITH GAUCHER DISEASE TYPE 1: FINAL EFFICACY AND SAFETY RESULTS FROM A PHASE 2 CLINICAL TRIAL AFTER 8 YEARS OF TREATMENT	Elena Lukina	Received

721-P	BIOLOGICAL CHARACTERIZATION OF ITP PATIENTS THAT ARE NON-RESPONDERS TO TRADITIONAL THERAPIES	Nuria Revilla	Received

725-P	ATORVASTATIN IMPROVE THE PROGNOSIS OF ADULT PATIENTS WITH CORTICOSTEROID-RESISTANT IMMUNE THROMBOCYTOPENIA VIA ENHANCING BONE MARROW ENDOTHELIAL CELL FUNCTION	Xie-Na Cao	Received

726-P	PLATELET DESIALYLATION IS A NOVEL MECHANISM AND A THERAPEUTIC TARGET IN THROMBOCYTOPENIA DURING SEPSIS: AN OPEN-LABEL, MULTICENTER, RANDOMIZED CONTROLLED TRIAL	Xin Li	Received

727-P	SAFETY AND EFFICACY OF LONG-TERM OPEN-LABEL DOSING OF SUBCUTANEOUS (SC) ROMIPLOSTIM IN CHILDREN WITH IMMUNE THROMBOCYTOPENIA (ITP)	James Bussel	Received

728-P	IMPACT OF VENETOCLAX ON THE QUALITY OF LIFE OF CLL PATIENTS RELAPSED/REFRACTORY TO B-CELL RECEPTOR (BCR) SIGNALING PATHWAY INHIBITOR TREATMENT	William Wierda	Received

729-P	THE ROLE OF PSYCHOLOGICAL VARIABLES FOR TYROSINE KINASE INHIBITORS (TKI) DISCONTINUATION IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS: IMPLICATION FOR MEDICAL DECISION MAKING PRACTICE	Silvia Riva	Received

730-P	BUDGET IMPACT ANALYSIS OF BIOSIMILAR RITUXIMAB (CT-P10) FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKAEMIA IN THE 28 EU MEMBER STATES	Fanni Rencz	Received

731-P	AN INVESTIGATION INTO THE NEEDS AND PRIORITIES OF PATIENTS WITH MULTIPLE MYELOMA DURING REMISSION – IMPLICATIONS FOR RE-DESIGNING PATIENT-CENTRED HEALTHCARE SYSTEMS.	Dunnya De-Silva	Received

732-P	COST-EFFECTIVENESS OF RITUXIMAB IN ADDITION TO STANDARD OF CARE CHEMOTHERAPY FOR ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA	Matthew Seftel	Received

734-P	RADIATION EXPOSURE FROM CT IMAGING AND CHILDHOOD LEUKEMIA: A NATIONWIDE CASE-CONTROL STUDY	Atte Nikkilä	Received

735-P	HEALTHCARE RESOURCE UTILIZATION WITH IXAZOMIB OR PLACEBO PLUS LENALIDOMIDE-DEXAMETHASONE IN THE RANDOMIZED, DOUBLE-BLIND, PHASE 3 TOURMALINE-MM1 STUDY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)	Parameswaran Hari	Received

736-P	MANAGEMENT, ECONOMIC AND SOCIAL IMPACT OF SUB-CUTANEOUS RITUXIMAB ADMINISTRATION IN LYMPHOPROLIFERATIVE MALIGNANCIES	Ombretta Annibali	Received

737-P	EFFECT OF IMPROVEMENTS OF SURVIVAL, POPULATION AGING AND IMWG´14 CRITERIA ON INCIDENCE AND PREVALENCE OF MULTIPLE MYELOMA	Violeta Martínez-Robles	Received

738-P	HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ISOLATED EXTRAMEDULLARY RELAPSE OF ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDREN	Maria Gabelli	Received

739-P	PREDICTIVE FACTORS FOR DEVELOPING VENO-OCCLUSIVE DISEASE IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH INOTUZUMAB OZOGAMICIN FOLLOWED BY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	Partow Kebriaei	Received

740-P	DEFIBROTIDE EFFICACY AND SAFETY IN PATIENTS WITH HEPATIC VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) DIAGNOSED AFTER DAY 21: ANALYSIS OF FINAL DATA FROM AN EXPANDED-ACCESS PROGRAM	Paul Richardson	Received

741-P	ALLO-HCT FOR PAROXYSMAL NOCTURNAL HEMOGLOBINURIA – 12 YEARS OF EXPERIENCE	Miroslaw Markiewicz	Received

743-P	HAPLOIDENTICAL ALLOGENEIC STEM CELL TRANSPLANT IN SEVERE THALASSEMIA PATIENTS	Suradej Hongeng	Received

744-P	AUGMENTATION OF FLUDARABINE AND BUSULFAN-BASED MYELOABLATIVE REGIMEN WITH THIOTEPA IMPROVES OUTCOMES WITH NO ADDED TOXICITY IN ALLOGENEIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA	Vipul sharad Sheth	Received

745-P	PROGNOSTIC TOOLS CAN PROVIDE PERSONALIZED OUTCOMES PREDICTION AFTER ALLOGENEIC HCT IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES	Christina Cho	Received

747-P	FACTORS PREDICTING GRAFT VERSUS HOST DISEASE-FREE, RELAPSE-FREE SURVIVAL AFTER ALLOGENEIC TRANSPLANTATION. COMPARISON ATTENDING TO TWO DIFFERENT DEFINITIONS AND BENEFICT OF HAPLOIDENTICAL DONOR.	Estefanía Pérez López	Received

748-P	EFFICACY AND SAFETY OF DEFIBROTIDE IN THE TREATMENT OF HEPATIC VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION: FINAL SUBGROUP RESULTS	Paul Richardson	Received

749-P	GENERATION OF IMMORTAL MURINE HEMATOPOIETIC STEM/PROGENITOR CELL LINES FROM TRANSGENIC MICE	Eszter Doma	Received

751-P	MESENCHYMAL STROMAL CELL IRRADIATION INTERFERES WITH THE ADIPOGENIC/OSTEOGENIC DIFFERENTIATION BALANCE IMPROVING THEIR HEMATOPOIETIC-SUPPORTING ABILITY	Silvia Preciado Pérez	Received

752-P	DYSFUNCTION OF BONE MARROW MESENCHYMAL STEM CELLS FROM PATIENTS WITH PROLONGED ISOLATED THROMBOCYTOPENIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION CAN BE IMPROVED BY N-ACETYL-L-CYSTEINE	Yang Song	Received

753-P	INHIBITORS OF APOPTOSIS PROTEINS (IAPS) MODULATE GASTROINTESTINAL GVHD IN MURINE EXPERIMENTAL BMT MODELS	Tomomi Toubai	Received

754-P	GRAFT-VERSUS HOST DISEASE (GVHD) DEVELOPMENT AFTER BONE MARROW TRANSPLANTATION IS NOT INFLUENCED BY TH9 CELLS	Gudrun Strauss	Received

755-P	IMPROVED HSC ENGRAFTMENT IN A MOUSE MODEL OF HEMATOPOIETIC STEM CELL GENE THERAPY MEDIATED BY MSCS	Maria Fernandez-Garcia	Received

756-P	EFFECT OF POMALIDOMIDE ON T CELL POLARIZATION IS MEDIATED THROUGH EPIGENETIC MODIFCATIONS.	Isabel Alvarez Laderas	Received

757-P	MESENCHYMAL STEM CELLS (MSCS) ATTENUATE CUTANEOUS SCLERODERMATOUS GRAFT-VERSUS-HOST DISEASE (SCL-GVHD) THROUGH INHIBITION OF IMMUNE CELL INFILTRATION IN A MOUSE MODEL	Ji-Young Lim	Received

758-P	C57BL/6 SUBTRAINS SHOW DIFFERENCES IN HEMATOPOIETIC REPOPULATION	Antonio Morales Hernandez	Received

759-P	GWAS RESULTS IN RED BLOOD CELL PHENOTYPES AND THEIR RELATIONSHIP WITH THROMBOSIS	Remacha Angel F.	Received

760-P	ESSENTIAL THROMBOCYTHEMIA (ET) AND POLYCYTHEMIA VERA (PV) PATIENTS SHOW AN INCREASED THROMBUS FORMATION IN A DYNAMIC MODEL OF PLATELET ADHESION	Alfonso Vignoli	Received

761-P	DOAC ASSOCIATED MAJOR GASTROINTESTINAL BLEEDING: REAL LIFE EXPERIENCE FROM A UNIVERSITY TEACHING HOSPITAL, UK	Buddhika Badugama	Received

763-P	INCIDENCE OF VENOUS THROMBOEMBOLISM IN PATIENTS UNDERGOING LOWER LIMB SURGICAL REVASCULARIZATION: IS THROMBOPROPHYLAXIS WARRANTED?	Pinar Smith	Received

764-P	THE ROLE OF INFLAMMATION IN THROMBOEMBOLISM IN RESECTABLE RENAL CELL CARCINOMA PATIENTS	Hyunkyung Park	Received

765-P	GENETIC AND ENVIRONMENTAL RELATIONSHIP BETWEEN VITAMIN B12, FOLATE AND HOMOCYSTEINE AND SUSCEPTIBILITY TO THROMBOSIS IN THE GAIT 2 PROJECT. RESULTS OF A GWAS ANALYSIS.	Remacha Angel F.	Received

766-P	CELLULAR ORIGIN OF CIRCULATING MICROPARTICLES (MP) ACCORDING TO SOMATIC MUTATIONS IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS (MPN)	Carmen Tartari	Received

767-P	ARE WE TESTING APPROPRIATELY FOR THE LUPUS ANTICOAGULANT?	Joe Sharif	Received

768-P	RESULTS OF USING BRIDGING THERAPY WITH SODIUM BEMIPARIN AT THERAPEUTIC-DOSE	María Almudena García Ruiz	Received

22nd Congress of EHA

22-25 June 2017 Madrid

About us

Search and consult posters online
in an exclusive section
for each poster

ACTIVE FROM 22/06/2017 TO 22/06/2017

Poster
Gallery

Upload
Poster

Featured Poster

Vote poster

Poster Discussion
Forum

DOI: 10.3252/pso.eu.22EHA.2017



		Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress.

About us

Terms and Conditions

Special Access

Commercial Web Access